Cannula

ClearPoint Neuro Congratulates Partner PTC Therapeutics on Being Granted Marketing Authorization by the European Commission for Upstaza™ - First Disease-Modifying Treatment for AADC Deficiency

Retrieved on: 
Thursday, July 21, 2022
Brain, Biopsy, Particular, AADC, GLOBE, Cerebrospinal fluid, PTC, Aromatic L-amino acid decarboxylase deficiency, U.S. Securities and Exchange Commission, CEO, Research, Royal commission, Solution, Partnership, CNS, Therapy, COVID-19, Genetic disorder, Head, Behavioral Problems, Paper, Cannula, Quality of life, Product, European Commission, CE, Anatomical pathology, Disability, FDA, Company, Cytarabine, Patient, Security (finance), Nasdaq, Life, Lists of diseases, PTC Therapeutics, Vomiting, Growth, Infection, CED, Medical device, Medicine

SOLANA BEACH, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the Company), a global therapy-enabling platform company providing navigation and delivery to the brain, congratulates partner PTC Therapeutics for being granted marketing authorization for Upstaza (eladocagene exuparvovec) by the European Commission.

Key Points: 
  • SOLANA BEACH, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the Company), a global therapy-enabling platform company providing navigation and delivery to the brain, congratulates partner PTC Therapeutics for being granted marketing authorization for Upstaza (eladocagene exuparvovec) by the European Commission.
  • The use of ClearPoint Neuros proprietary CE Marked SmartFlow Neuro Cannula for minimally invasive infusion of the gene therapy is included in the Upstaza SmPC (Summary of Product Characteristics).
  • The marketing authorization, approved for patients 18 months and older, is applicable to all 27 European Union member states, as well as Iceland, Norway and Liechtenstein.
  • The approval of Upstaza by the European Commission will have an immense impact on patients, their families, and the global gene therapy research community.

PDO Max® Launches On-Demand e-Learning Courses for PDO Thread Procedures

Retrieved on: 
Tuesday, July 19, 2022
MAX, PDO, Face, FDA, Cannula, Overalls, Medicine

SYRACUSE, N.Y., July 19, 2022 /PRNewswire/ -- PDO Max, Inc., a leader in FDA cleared Polydioxanone (PDO) threads-in-cannula medical devices for non-surgical tissue repositioning, now offers an e-Learning platform with hours of PDO thread training video content for the face and body.

Key Points: 
  • SYRACUSE, N.Y., July 19, 2022 /PRNewswire/ -- PDO Max, Inc., a leader in FDA cleared Polydioxanone (PDO) threads-in-cannula medical devices for non-surgical tissue repositioning, now offers an e-Learning platform with hours of PDO thread training video content for the face and body.
  • "PDO threads are an evolving medical device and procedure; there is always something new to learn with various thread types and techniques for different vector designs and procedures," explains PDO Max Founder Giovanna McCarthy.
  • PDO Max offers hands-on individual instructional courses along with e-Learning courses, which cover the application of PDO thread techniques.
  • For more information regarding PDO MAX threads, to place an order, or to schedule a training, please contact PDO Max at 800-670-0225 or visit https://www.pdomax.com .

InventHelp Inventor Develops Way to Wear Glasses & Support a Nasal Cannula (MHO-130)

Retrieved on: 
Tuesday, June 21, 2022
Cannula, Population, Multimedia, Ninth Street, Sale, Petroleum jelly, Publishing

View original content to download multimedia:https://www.prnewswire.com/news-releases/inventhelp-inventor-develops-wa...

Key Points: 
  • I wanted to create a more comfortable way to wear glasses and support nasal cannula," said the inventor, from Dallas, Texas, "so I invented the NASAL CANNULA SUPPORT.
  • My design would reduce stress on your ears and it provides secure placement of the nasal cannula for maximal effect."
  • The invention provides an improved way to support a nasal cannula when wearing eyeglasses.
  • In doing so, it eliminates the common problems associated with the cannula and glasses sharing space behind the ear of the wearer.

Global Cannula Market Size, Share & Trends Analysis Report 2022-2030 Featuring Medtronic, Becton Dickinson, Edward Lifesciences, Livanova, Smiths Medical, & Boston Scientific - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 25, 2022
Medical Supplies, Health, Conditional sentence, Hospital, Patient, Government, Cannula, USD, COVID-19, Plastic, Awareness, Adoption, CAGR, Prevalence, Growth, Pharmaceutical industry, Medical device, Dermatology

The "Cannula Market Size, Share & Trends Analysis Report by Product (Cardiac, Dermatology, Nasal, and Others), by Type, by Material, by Size, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cannula Market Size, Share & Trends Analysis Report by Product (Cardiac, Dermatology, Nasal, and Others), by Type, by Material, by Size, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global cannula market size is expected to reach USD 294.6 million by 2030 at a 7.3% CAGR.
  • Increase in the prevalence of lifestyle diseases and an increase in awareness about minimally invasive surgeries are primary factors driving the growth of the cannula market.
  • the straight cannulae accounted for the highest market share in 2021 due to the high adoption rate as it is simpler to use.

Kleiner Device Labs' KG2 Surge Flow-Thru Interbody System Awarded Bronze in the 2022 Medical Design Excellence Awards

Retrieved on: 
Wednesday, April 13, 2022
CEO, MDEA, MD, Work, Medicine, KG2, Implant, PLIF, FDA, Industry, Cannula, Genesis Revisited II, Medical device, Antibiotics

The annual MDEA competition recognizes products that are moving the $450 billion medical device industry forward through live-saving innovations and remarkable technological advancements.  The MDEAs are determined each year by an independent panel--clinicians, engineers and designers—to select finalists as well as winners in each of 10 product categories. 

Key Points: 
  • INCLINE VILLAGE, Nev., April 13, 2022 /PRNewswire/ -- Kleiner Device Labs today announced that its new KG2Surgeflow-thru interbody system was recognized with the Bronze award in the 2022 Medical Design Excellence Awards (MDEA) in the Implant and Tissue-Replacement Products category.
  • The KG2 system maximizes total bone graft delivery volume and streamlines TLIF and PLIF spinal fusion procedures.
  • The FDA-cleared KG2 Surge system streamlines the implant delivery and grafting steps in lumbar spinal fusion procedures.
  • Kleiner Device Labs is creating new instruments and devices to advance minimally invasive spine surgery and improve outcomes and costs.

InventHelp Inventor Develops Comfortable Way to Secure Nasal Cannula (JMC-2373)

Retrieved on: 
Friday, April 8, 2022
Multimedia, Ninth Street, Caregiver, National, Skin, Cannula, Sale, Patient

PITTSBURGH, April 8, 2022 /PRNewswire/ --"I wanted to create an accessory to secure nasal cannula and prevent it from slipping," said an inventor, from Anacoco, La., "so I invented the NOSE CANULA ASSIST.

Key Points: 
  • PITTSBURGH, April 8, 2022 /PRNewswire/ --"I wanted to create an accessory to secure nasal cannula and prevent it from slipping," said an inventor, from Anacoco, La., "so I invented the NOSE CANULA ASSIST.
  • The patent-pending invention provides a more comfortable way to hold nasal cannula in place.
  • In doing so, it eliminates the need to tighten cannula or use tape.
  • The original design was submitted to the National sales office of InventHelp.

Kleiner Device Labs' KG2 Surge Flow-Thru Interbody System Named Finalist for MD+DI Medical Design Excellence Award

Retrieved on: 
Thursday, March 31, 2022
PLIF, Medicine, KG2, Hospital, Implant, Medtech, Surgeon, Cannula, Engineering, Patient, Medical device

INCLINE VILLAGE, Nev., March 31, 2022 /PRNewswire/ -- Kleiner Device Labs today announced that its new KG2TM SurgeTM flow-thru interbody system has been selected as a finalist in the 2022 Medical Design Excellence awards in the Implant and Tissue-Replacement Products category.

Key Points: 
  • INCLINE VILLAGE, Nev., March 31, 2022 /PRNewswire/ -- Kleiner Device Labs today announced that its new KG2TM SurgeTM flow-thru interbody system has been selected as a finalist in the 2022 Medical Design Excellence awards in the Implant and Tissue-Replacement Products category.
  • Medical Device + Diagnostic Industry (MD+DI) sponsors the annual awards to recognize superior design and engineering of products in the MedTech industry that improve health outcomes, quality and accessibility.
  • The KG2 Surge system streamlines the implant delivery and grafting steps in lumbar spinal fusion procedures.
  • The system comes with the interbody device pre-assembled with the cannula in a single-use sterile tray.

Synergy Biomedical Launches BIOSPHERE® MIS II, Next Generation Minimally Invasive Bone Graft Delivery System

Retrieved on: 
Tuesday, March 1, 2022
Surgery, Health, Medical Devices, Surgeon, Technology, LLC, Solution, Efficiency, UCLA, Spine, Biomedicine, Cannula, UCLA Health, Toy, Medical device

Synergy Biomedical, LLC, a developer of innovative biomaterial products, today announced the launching of BIOSPHERE MIS II, Next Generation Minimally Invasive Bone Graft Delivery System.

Key Points: 
  • Synergy Biomedical, LLC, a developer of innovative biomaterial products, today announced the launching of BIOSPHERE MIS II, Next Generation Minimally Invasive Bone Graft Delivery System.
  • Leveraging off the proven success of the first-generation design, BIOSPHERE MIS II utilizes a pre-loaded bone graft cannula and a streamlined trigger-based system as a bone graft delivery solution that is optimized for the unique challenges of minimally invasive surgery.
  • The BIOSPHERE MIS II system permits strategic and controlled placement of Synergys regarded next-generation synthetic bone graft product (BIOSPHERE PUTTY) in open, mini-open, and percutaneous minimally invasive settings.
  • Continuing the proven success of the original BIOSPHERE MIS System, the BIOSPHERE MIS II bone graft delivery system again consists of several new innovative features.

Capillary Biomedical Receives ISO 13485:2016 Quality System Certification

Retrieved on: 
Tuesday, March 1, 2022
FDA, Diabetes, Health, Medical Devices, ISO, CE marking, Quality, Food, Insulin, Organization, Quality of life, Hospital, American Diabetes Association, Certification, FDA, ADA, Sale, Pain, Time, Inflammation, Saint Vincent, US Foods, Technology, Diabetes, News, Cannula, IDE, St. Vincent's Hospital, Medical device, EU

Medical device developer Capillary Biomedical, Inc. (CapBio) has announced that it has received ISO 13485:2016 (Medical devices Quality management systems Requirements for regulatory purposes) certification, indicating that CapBios quality management system conforms to the recognized international standard for the design, manufacture, and distribution of medical devices.

Key Points: 
  • Medical device developer Capillary Biomedical, Inc. (CapBio) has announced that it has received ISO 13485:2016 (Medical devices Quality management systems Requirements for regulatory purposes) certification, indicating that CapBios quality management system conforms to the recognized international standard for the design, manufacture, and distribution of medical devices.
  • The certification demonstrates that the companys quality system is aligned with EU regulations and ready to support commercialization of the companys SteadiSet infusion set in the EU upon CE Marking.
  • ISO 13485:2016 is an internationally recognized quality standard intended to provide a quality framework focused on the consistent design, development, servicing and sale of medical devices.
  • This ISO certification is evidence of our commitment to the highest standards of product performance, quality, consistency, and reliability, said CapBio CEO Paul Strasma.

PDO MAX® Reimagines the PDO Thread Lift with New "Lock In" Thread

Retrieved on: 
Tuesday, February 15, 2022
Lifting, Patient, Collagen, MAX, Scalp, PDO, Velcro, FDA, Cannula, Skin

SYRACUSE, N.Y., Feb. 15, 2022 /PRNewswire/ --PDO MAX, Inc. launches a more durable PDO thread device to the aesthetic market with Levo Lock: FDA cleared thread-in-cannula that supports while it also enhances the standard PDO thread "lift."

Key Points: 
  • SYRACUSE, N.Y., Feb. 15, 2022 /PRNewswire/ --PDO MAX, Inc. launches a more durable PDO thread device to the aesthetic market with Levo Lock: FDA cleared thread-in-cannula that supports while it also enhances the standard PDO thread "lift."
  • Levo Lock is an 18G x 100mm thread-in-cannula that creates dramatic and longer-lasting results for popular PDO thread brow-, cheek-, and jawline "lift" procedures.
  • PDO Max offers hands-on individual instructional courses, which cover the application of PDO thread techniques.
  • For more information regarding PDO MAX threads, to place an order, or to schedule a training, please contact PDO MAX at 800-670-0225 or visit https://www.pdomax.com .